___

• 1. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene kit, a new cell sur- face-receptor tyrosine kinase for unidentified ligand. EMBO J 1987;6:3341 – 51. 2. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, et al. Identification of a ligand for the c-kit proto-on- cogene. Cell 1990;63:167 – 74. 3. d’Auriol L, Mattei MG, Andre C, Galibert F. Localization of the human c-kit protooncogene on the q11–q12 region of chro- mosome 4. Hum Genet 1988;78:374 – 6. 4. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, et al. C-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995;91:6610 – 30. 5. Dudani S, Kalhan S, Sharma S, Gupta A. Gastrointestinal stromal tumours (GIST)-pathology and clinical applications of recent molecular advences-A perspective review. Çağdaş Tıp Dergisi 2014;4:85-90. 6. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stroma. Cancer Res 2001;61(22):8118 – 21. 7. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinibe mesylate (STI571) Eur J Cancer 2002;38 (Suppl 5):52–59. 8. Druker BJ, Sawyers CL., Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chro- mosome N Engl J Med 2001;344:1038–42. 9. DeMatteo RP. The GIST of targeted cancer therapy: a tumor gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular nhibitor (STI571) Ann Surg Oncol 2002;9:831–3. 10. Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001;28 (Suppl 17):19–26. 11. Heinrich MC., Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT ac- tivation and cytogenetic alterations. Hum Pathol 2002;33:484 – 95. 12. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhi- bition of KIT tyrosine kinase activity: a novel molecular ap- proach to treatment of KIT-positive malignancies J Clin Oncol 2002;20:1692–703. 13. Elmore LW, Domson K, Moore JR, Kornstein M, Burks RT. Expression of c-kit (CD117) in benign and malignant human endometrial epithelium. Arch Pathol Lab Med 2001;125:146– 51. 14. Scobie JV, Acs G, Bandera CA, Blank SV, Wheeler JE, Pas- ha TL, et al. C-kit immunoreactivity in endometrial adenocar- cinomas and its clinicopathological significance. Int J Gynecol Pathol 2003;22:149–50. 15. Alkushi A, Irving J, Hsu F, Dupuis B, Liu CL, Rijn M, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray Virchows Arch 2003;442: 271–7. 16. Winter WE III, Seidman JD, Krivak TC, ChauhanS, Carlson JV, Rose, GS et al. Clinicopathological analysis of c-kit expres- sion in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003;91:3–8. 17. Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol 2003;91:9–14. 18. Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int. J Gynecol Pathol 2003;22:181–4. 19. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Be- vers MV, Wolf JK, et al.A phase II trial of cisplatin, ifosfami- de, and mesna in patients with advanced or recurrent uterine malignant mixed Mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 2003;90:529–36. 20. Huh WK, Conner MG, Straughn Jr. JM, Leath CA, Barnes MN, Alvarez RD, et al. Immunohistochemical evaluation of the c Kit proto-oncogene in sarcomas of the uterus. Gynecol Oncol 2002;84:531 [abstract]. 21. Constantinescu M, Turbat-Herrera EA, Nordberg ML, et al. CD117 and CD34 expression by immunohistochemistry in uterine mixed Mullerian tumors Lab Invest 2003;83:186A–7A [abstract]. 22. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Ka- samatsu T, et al. Different expression patterns of KIT, EGFR, and HER-2 (c erbB-2) oncoproteins between epithelial and me- senchymal components in uterine carcinosarcoma. Cancer Sci 2003;94:986–91. 23. Leath CA III, Straughn Jr. JM, Conner MG, Barnes III MN, Alvarez RD, Partridge EE, et al. Immunohistochemical evalu- ation of the c-kit proto-oncogene in sarcomas of the uterus: a case series J Reprod Med 2004;49:71–5. 24. Gadducci A, Sartori E, Landoni F, Zola P et al. The prog- nostic relevance of histological type in uterine sarcomas: a Co- operation Task Force (CTF) multivariate analysis of 249 cases Eur. J. Gynecol. Oncol 2002;23:295–9. 25. Lucas DR, al-Abbadi M, Tabaczka P, Hamre MR, Weaver DW, Mott MJ. c-Kit expression in desmoid fibromatosis. Com- parative immunohistochemical evaluation of two commercial antibodies Am. J. Clin. Pathol 2003;119:339–45. 26. Wang L, Felix JC, Lee JL, Tan PY, Tourgeman DE, O’Meara AT, et al. The proto-oncogene c-kit is expressed in leiomyosar- comas of the uterus. Gynecol. Oncol 2003;90:402–6. 27. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohis- tochemical spectrum of GISTs at different sites and their diffe- rential diagnosis with reference to CD117 (KIT). Mod. Pathol 2000;13:1134–42. 28. Abargel a, Avinoach I, Kravtsov V, Boaz M, Glezerman M, Menczer J. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int. J. Gynecol. Cancer 2004;14: 354–9. 29. Bamberger A, Riethdorf L, Milde-Langosch K, Bamberger CM, Thuneke I, Erdmann I, et al. Strongly reduced expression of the cell cycle inhibitor in endometrial neoplasia Virchows Arch 1999;443:423–8. 30. Raspollini MR, Villanucci A, Amunni G, Paglierani M, Tad- deiA, Taddei GL. C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus J. Chemother 2003;15:81–4. 31. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int. J. Gynecol. Cancer 2002;12:687–90. 32. Kounelis S, Jones MW, Papadaki P, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcoma (malignant mixed Mullerian tumors) of the genital tract: comparative molecular analy- sis of epithelial and mesenchymal components. Hum. Pathol 1998;29:82–7. 33. Guarino M, Giordano F, Pallotti F, Polizzoti G, Tricomi P, Cristofori E. Malignant mixed Mullerian tumor of the uterus. Feature favoring its origin from a common cell clone and an epithelial to mesenchymal transformation of histogenesis. Tu- mori 1998;84:391–7. 34. Szukala SA, Marks JR, Burchette JL, Elbendery AA, Krig- man HR. Co-expression of p53 by epithelial and stromal ele- ments in carcinosarcoma of the female genital tract: an im- munohistochemical study of 19 cases. In. J. Gynecol. Cancer 1999;9:131–6. 35. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders Hum. Pathol 1998;29:498– 504.